Adipose depots, not disease-related factors, account for skeletal muscle insulin sensitivity in established and treated rheumatoid arthritis

• Published in: Journal of rheumatology Vol. 41; no. 10; p. 1974
• Main Authors: AbouAssi, Hiba, Tune, K Noelle, Gilmore, Brian, Bateman, Lori A, McDaniel, Gary, Muehlbauer, Michael, Huebner, Janet L, Hoenig, Helen M, Kraus, Virginia B, St Clair, E William, Kraus, William E, Huffman, Kim M
• Format: Journal Article
• Language: English
• Published: Canada 01.10.2014
• Subjects: Adipose Tissue - metabolism; Adiposity - physiology; Adult; Aged; Antirheumatic Agents - therapeutic use; Arthritis, Rheumatoid - drug therapy; Arthritis, Rheumatoid - metabolism; Cross-Sectional Studies; Female; Glucose Tolerance Test; Humans; Insulin Resistance - physiology; Interleukin-18 - blood; Interleukin-6 - blood; Male; Middle Aged; Muscle, Skeletal - metabolism; Tumor Necrosis Factor-alpha - blood; INSULIN RESISTANCE; BODY COMPOSITION; SKELETAL MUSCLE; PHYSICAL ACTIVITY
• ISSN: 0315-162X
• DOI: 10.3899/jrheum.140224

In prior reports, individuals with rheumatoid arthritis (RA) exhibited increased insulin resistance. However, those studies were limited by either suboptimal assessment methods for insulin sensitivity or a failure to account for important determinants such as adiposity and lack of physical activity. Our objectives were to carefully assess, compare, and determine predictors of skeletal muscle insulin sensitivity in RA, accounting for adiposity and physical activity. Thirty-nine individuals with established (seropositive or erosions) and treated RA and 39 controls matched for age, sex, race, body mass index, and physical activity underwent a frequently sampled intravenous glucose tolerance test to determine insulin sensitivity. Inflammation, body composition, and physical activity were assessed with systemic cytokine measurements, computed tomography scans, and accelerometry, respectively. Exclusions were diabetes, cardiovascular disease, medication changes within 3 months, and prednisone use over 5 mg/day. This investigation was powered to detect a clinically significant, moderate effect size for insulin sensitivity difference. Despite elevated systemic inflammation [interleukin (IL)-6, IL-18, tumor necrosis factor-α; p < 0.05 for all], persons with RA were not less insulin sensitive [SI geometric mean (SD): RA 4.0 (2.4) vs control 4.9 (2.1)*10(-5) min(-1)/(pmol/l); p = 0.39]. Except for visceral adiposity being slightly greater in controls (p = 0.03), there were no differences in body composition or physical activity. Lower insulin sensitivity was independently associated with increased abdominal and thigh adiposity, but not with cytokines, disease activity, duration, disability, or disease-modifying medication use. In established and treated RA, traditional risk factors, specifically excess adiposity, play more of a role in predicting skeletal muscle insulin sensitivity than do systemic inflammation or other disease-related factors.